Maynard Um
-
-
-
-
-
-
-
Bicara Therapeutics Inc (BCAX) PT Raised to $39 at Morgan Stanley
-
-
-
-
-
-
-
Bicara reports three-year survival data for cancer drug combo
-
-
-
-
-
-
-
Bicara Therapeutics Inc (BCAX) stock an 'attractive investment opportunity': Analyst
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Bicara Therapeutics Inc (BCAX)
-
-
-
-
-
-
-
Stifel Reiterates Bicara Therapeutics Inc (BCAX) at Buy, Still Confident of Ficerafusp Thesis
-
-
-
-
-
-
-
Piper Sandler Starts Bicara Therapeutics Inc (BCAX) at Overweight
-
-
-
-
-
-
-
Bicara Therapeutics (BCAX) publishes updated data from Phase 1/1b trial of Ficerafusp alfa
-
466,305 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


